Keywords: Array BioPharma, Novartis, MEK inhibitors, ARRY-162, Cancer, Diabetes

Array BioPharma set to earn up to $467 million from oncology deal with Novartis

Article | 20 April 2010

Print This

US drug developer Array BioPharma revealed yesterday that it has entered into an agreement with Swiss drug giant Novartis for ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in